ConductScience.org, home

Comparison · NCT01714817-8a4f7255

Abatacept IV vs Placebo IV: Number of Participants With Abatacept Induced Antibody Response Over Time in the Double-blind Period

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Abatacept IV vs Placebo IV: Number of Participants With Abatacept Induced Antibody Response Over Time in the Double-blind Period. Trial comparisons, record NCT01714817-8a4f7255. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01714817-8a4f7255

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.03470.01690.0698wilson
Risk in group 20.04430.02350.0821wilson
Risk difference, group 1 minus group 2-0.00968-0.05140.0312newcombe hybrid score
Risk ratio, group 1 over group 20.7820.2972.06log
Odds ratio, group 1 over group 20.7740.2832.12log
Number needed to treat, for one fewer participant with the outcome on Abatacept IV than on Placebo IV103from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Abatacept IV
Abatacept 30 mg/kg injection by intravenous on Days 1,15, 29, and 57, followed by a weight-tiered dose approximating 10mg/kg injection by intravenous every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 weeks
7202OG000
Group 2Placebo IV
Placebo matching with Abatacept injection by intravenous on Days 1,15, 29, and 57, followed by every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 Weeks
9203OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Abatacept Induced Antibody Response Over Time in the Double-blind Period
Description
Participants who experienced a positive antibody response relative to baseline (ECL Assay)
Time frame
Day 365, Day 729
Population
All treated participants in the immunogenicity analysis population for Year 1.~Note: Study terminated, Year 2 data not collected

Source ClinicalTrials.gov

Trial

Title
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
NCT number
NCT01714817
Phases
PHASE3
Conditions
Lupus Nephritis
Interventions
BMS-188667, Mycophenolate mofetil, Prednisone, Placebo matching with BMS-188667
Lead sponsor
Bristol-Myers Squibb
Results first posted
2017-12-21

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01714817-8a4f7255